BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: von Weizsäcker F, Blum HE. Out of control: hepatitis B reactivation by transarterial treatment of hepatocellular carcinoma. J Hepatol. 2004;41:482-484. [PMID: 15336452 DOI: 10.1016/j.jhep.2004.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World J Hepatol 2016; 8(8): 385-394 [PMID: 27004086 DOI: 10.4254/wjh.v8.i8.385] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
2 Zhang S, Liu J, Zhu J, Xiao M, Lu C, Ni R, Qu L. Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis. Japanese Journal of Clinical Oncology 2019;49:646-55. [DOI: 10.1093/jjco/hyz046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Sun Z, Li G, Ai X, Luo B, Wen Y, Zhao Z, Dong S, Guan J. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol 2011;79:164-74. [PMID: 20719529 DOI: 10.1016/j.critrevonc.2010.07.019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]